Sara Llufriu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9227802/publications.pdf Version: 2024-02-01



SADA LI HEDI H

#	Article	IF	CITATIONS
1	Prognosis of a second clinical event from baseline MRI in patients with a CIS: a multicenter study using a machine learning approach. Neuroradiology, 2022, 64, 1383-1390.	2.2	2
2	Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology. Frontiers in Immunology, 2022, 13, 842354.	4.8	1
3	Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder. Journal of Personalized Medicine, 2022, 12, 743.	2.5	6
4	Applying multilayer analysis to morphological, structural, and functional brain networks to identify relevant dysfunction patterns. Network Neuroscience, 2022, 6, 916-933.	2.6	10
5	Longitudinal Retinal Changes in <scp>MOGAD</scp> . Annals of Neurology, 2022, 92, 476-485.	5.3	20
6	A NOTCH3 homozygous nonsense mutation in familial Sneddon syndrome with pediatric stroke. Journal of Neurology, 2021, 268, 810-816.	3.6	11
7	A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center. Journal of Autoimmunity, 2021, 117, 102580.	6.5	23
8	Taking care of kidney transplant recipients during the COVIDâ€19 pandemic: Experience from a medicalized hotel. Clinical Transplantation, 2021, 35, e14132.	1.6	5
9	Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability. Multiple Sclerosis Journal, 2021, 27, 1706-1716.	3.0	8
10	Incidence and Impact of COVID-19 in MS. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	29
11	Cortical fractal dimension predicts disability worsening in Multiple Sclerosis patients. NeuroImage: Clinical, 2021, 30, 102653.	2.7	21
12	Accelerated white matter lesion analysis based on simultaneous <i>T</i> ₁ and <i>T</i> ₂ ^{â^—} quantification using magnetic resonance fingerprinting and deep learning. Magnetic Resonance in Medicine, 2021, 86, 471-486.	3.0	12
13	In Vivo Molecular Changes in the Retina of Patients With Multiple Sclerosis. , 2021, 62, 11.		7
14	Lesion probability mapping in MS patients using a regression network on MR fingerprinting. BMC Medical Imaging, 2021, 21, 107.	2.7	3
15	Regional grey matter microstructural changes and volume loss according to disease duration in multiple sclerosis patients. Scientific Reports, 2021, 11, 16805.	3.3	17
16	Open-access quantitative MRI data of the spinal cord and reproducibility across participants, sites and manufacturers. Scientific Data, 2021, 8, 219.	5.3	27
17	Generic acquisition protocol for quantitative MRI of the spinal cord. Nature Protocols, 2021, 16, 4611-4632.	12.0	65
18	Fully automated delineation of the optic radiation for surgical planning using clinically feasible sequences. Human Brain Mapping, 2021, 42, 5911-5926.	3.6	5

#	Article	IF	CITATIONS
19	CSF Chitinase 3–Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	15
20	Diffusion-Weighted Imaging: Recent Advances and Applications. Seminars in Ultrasound, CT and MRI, 2021, 42, 490-506.	1.5	30
21	A Prospective Cohort of SARS-CoV-2-Infected Health Care Workers: Clinical Characteristics, Outcomes, and Follow-up Strategy. Open Forum Infectious Diseases, 2021, 8, ofaa592.	0.9	7
22	Dynamics and Predictors of Cognitive Impairment along the Disease Course in Multiple Sclerosis. Journal of Personalized Medicine, 2021, 11, 1107.	2.5	8
23	Using Acute Optic Neuritis Trials to Assess Neuroprotective and Remyelinating Therapies in Multiple Sclerosis. JAMA Neurology, 2020, 77, 234.	9.0	17
24	Rebound of multiple sclerosis activity after fingolimod withdrawal due to planning pregnancy: Analysis of predisposing factors. Multiple Sclerosis and Related Disorders, 2020, 38, 101483.	2.0	23
25	Characterization of multiple sclerosis lesions with distinct clinical correlates through quantitative diffusion MRI. NeuroImage: Clinical, 2020, 28, 102411.	2.7	11
26	Impact of Cognitive Reserve and Structural Connectivity on Cognitive Performance in Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 581700.	2.4	8
27	Retinal and brain damage during multiple sclerosis course: inflammatory activity is a key factor in the first 5 years. Scientific Reports, 2020, 10, 13333.	3.3	20
28	Increased power by harmonizing structural MRI site differences with the ComBat batch adjustment method in ENIGMA. NeuroImage, 2020, 218, 116956.	4.2	135
29	Targeted resequencing reveals rare variants enrichment in multiple sclerosis susceptibility genes. Human Mutation, 2020, 41, 1308-1320.	2.5	1
30	Abstract 15640: Long Term Moderate, but Not Intense, Exercise Improves Cognitive Brain Health. Study in a Rat Model. Circulation, 2020, 142, .	1.6	0
31	Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. Journal of Neuroinflammation, 2019, 16, 134.	7.2	115
32	Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 8463-8470.	7.1	112
33	Late-onset neuromyelitis optica spectrum disorder. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	6.0	44
34	Modified connectivity of vulnerable brain nodes in multiple sclerosis, their impact on cognition and their discriminative value. Scientific Reports, 2019, 9, 20172.	3.3	10
35	Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults. Journal of Neurology, 2019, 266, 806-815.	3.6	47
36	Spanish validation of the telephone assessed Expanded Disability Status Scale and Patient Determined Disease Steps in people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 27, 333-339.	2.0	17

#	Article	IF	CITATIONS
37	Frequency and relevance of IgM, and IgA antibodies against MOG in MOG-IgG-associated disease. Multiple Sclerosis and Related Disorders, 2019, 28, 230-234.	2.0	18
38	Hippocampal-related memory network in multiple sclerosis: A structural connectivity analysis. Multiple Sclerosis Journal, 2019, 25, 801-810.	3.0	17
39	Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain, 2018, 141, 1085-1093.	7.6	115
40	Time efficient whole-brain coverage with MR Fingerprinting using slice-interleaved echo-planar-imaging. Scientific Reports, 2018, 8, 6667.	3.3	29
41	Cortical microstructural changes along the Alzheimer's disease continuum. Alzheimer's and Dementia, 2018, 14, 340-351.	0.8	122
42	Assessing Biological and Methodological Aspects of Brain Volume Loss in Multiple Sclerosis. JAMA Neurology, 2018, 75, 1246.	9.0	32
43	Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurology, The, 2018, 17, 760-772.	10.2	422
44	Combined walking outcome measures identify clinically meaningful response to prolonged-release fampridine. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641878000.	3.5	7
45	Magnetic resonance markers of tissue damage related to connectivity disruption in multiple sclerosis. NeuroImage: Clinical, 2018, 20, 161-168.	2.7	22
46	Predictors of vision impairment in Multiple Sclerosis. PLoS ONE, 2018, 13, e0195856.	2.5	21
47	Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates. Multiple Sclerosis Journal, 2018, 24, 1843-1851.	3.0	77
48	Vanishing spinal cord after varicella-zoster virus myelitis. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e364.	6.0	1
49	Impairment of decision-making in multiple sclerosis: A neuroeconomic approach. Multiple Sclerosis Journal, 2017, 23, 1762-1771.	3.0	8
50	Structural networks involved in attention and executive functions in multiple sclerosis. NeuroImage: Clinical, 2017, 13, 288-296.	2.7	87
51	Liver injury and glatiramer acetate, an uncommon association: case report and literature review. Therapeutic Advances in Neurological Disorders, 2017, 10, 367-372.	3.5	9
52	Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-309690.	1.9	90
53	Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders. Therapeutic Advances in Neurological Disorders, 2016, 9, 436-440.	3.5	43
54	Power estimation for non-standardized multisite studies. NeuroImage, 2016, 134, 281-294.	4.2	36

#	Article	IF	CITATIONS
55	Visual field impairment captures disease burden in multiple sclerosis. Journal of Neurology, 2016, 263, 695-702.	3.6	14
56	Enhanced mirror activity in â€~crossed' reaction time tasks in multiple sclerosis. Clinical Neurophysiology, 2016, 127, 2001-2009.	1.5	5
57	Pituitary-ovary axis and ovarian reserve in fertile women with multiple sclerosis: A pilot study. Multiple Sclerosis Journal, 2016, 22, 564-568.	3.0	36
58	Improved Framework for Tractography Reconstruction of the Optic Radiation. PLoS ONE, 2015, 10, e0137064.	2.5	39
59	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis Journal, 2015, 21, 1013-1024.	3.0	249
60	Lipidâ€specific immunoglobulin <scp>M</scp> bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. Annals of Neurology, 2015, 77, 447-457.	5.3	48
61	Intense immunosuppression for the treatment of an immune reconstitution inflammatory syndrome-like exacerbation after natalizumab withdrawal: a case report. Journal of Neurology, 2015, 262, 219-221.	3.6	3
62	Dynamics of retinal injury after acute optic neuritis. Annals of Neurology, 2015, 77, 517-528.	5.3	142
63	Long-term follow-up of immunotherapy-unresponsive recurrent tumefactive demyelination. Journal of the Neurological Sciences, 2015, 352, 127-128.	0.6	6
64	Walking function in clinical monitoring of multiple sclerosis by telemedicine. Journal of Neurology, 2015, 262, 1706-1713.	3.6	22
65	Autoimmune post–herpes simplex encephalitis of adults and teenagers. Neurology, 2015, 85, 1736-1743.	1.1	226
66	Color vision impairment in multiple sclerosis points to retinal ganglion cell damage. Journal of Neurology, 2015, 262, 2491-2497.	3.6	35
67	Defective sensorimotor integration in preparation for reaction time tasks in patients with multiple sclerosis. Journal of Neurophysiology, 2015, 113, 1462-1469.	1.8	17
68	Onset-adjusted incidence of multiple sclerosis in the Girona province (Spain): Evidence of increasing risk in the south of Europe. Journal of the Neurological Sciences, 2015, 359, 146-150.	0.6	8
69	Abnormal Control of Orbicularis Oculi Reflex Excitability in Multiple Sclerosis. PLoS ONE, 2014, 9, e103897.	2.5	14
70	Randomized Placebo-Controlled Phase II Trial of Autologous Mesenchymal Stem Cells in Multiple Sclerosis. PLoS ONE, 2014, 9, e113936.	2.5	131
71	The multiple sclerosis visual pathway cohort: understanding neurodegeneration in MS. BMC Research Notes, 2014, 7, 910.	1.4	26
72	Cognitive functions in multiple sclerosis: impact of gray matter integrity. Multiple Sclerosis Journal, 2014, 20, 424-432.	3.0	47

#	Article	IF	CITATIONS
73	Longitudinally extensive myelitis in a patient with characteristic autoantibody profile of systemic lupus erythematosus: a challenging etiological diagnosis. Lupus, 2014, 23, 1555-1556.	1.6	1
74	Magnetic Resonance Spectroscopy Markers of Disease Progression in Multiple Sclerosis. JAMA Neurology, 2014, 71, 840.	9.0	57
75	Transâ€synaptic axonal degeneration in the visual pathway in multiple sclerosis. Annals of Neurology, 2014, 75, 98-107.	5.3	206
76	Colour vision impairment is associated with disease severity in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1207-1216.	3.0	35
77	Analysis of prognostic factors associated with longitudinally extensive transverse myelitis. Multiple Sclerosis Journal, 2013, 19, 742-748.	3.0	35
78	Retrograde retinal damage after acute optic tract lesion in MS. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 824-826.	1.9	22
79	Changes in Your Breathing Can Change Your Brain. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 763-764.	5.6	2
80	White and Gray Matter Impairment in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 207-208.	5.6	0
81	Analysis of antibodies to surface epitopes of contactin-2 in multiple sclerosis. Journal of Neuroimmunology, 2012, 244, 103-106.	2.3	21
82	Influence of Corpus Callosum Damage on Cognition and Physical Disability in Multiple Sclerosis: A Multimodal Study. PLoS ONE, 2012, 7, e37167.	2.5	68
83	Rapidly progressive diffuse Lewy body disease. Movement Disorders, 2011, 26, 1316-1323.	3.9	56
84	Reply: Rapidly progressing diffuse Lewy body disease. Movement Disorders, 2011, 26, 2585-2585.	3.9	0
85	T2 hypointense rims and ring-enhancing lesions in MS. Multiple Sclerosis Journal, 2010, 16, 1317-1325.	3.0	16
86	Plasma exchange for acute attacks of CNS demyelination. Neurology, 2009, 73, 949-953.	1.1	174
87	Cytotoxic effect of neuromyelitis optica antibody (NMO-lgG) to astrocytes: An in vitro study. Journal of Neuroimmunology, 2009, 215, 31-35.	2.3	91
88	Familial Sneddon's syndrome with microbleeds in MRI. BMJ Case Reports, 2009, 2009, bcr2007131912-bcr2007131912.	0.5	2
89	Familial Sneddon's syndrome with microbleeds in MRI. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 962-962.	1.9	9